Live Activities

Impulse Control Disorders in Parkinson's Disease

Date: October 25-26, 2012
Location: Boston, Massachusetts, USA

Description

The goal of this conference was to bring together clinical and preclinical experts from various research backgrounds to develop a strategic plan for the study of highly destructive Impulse Control Disorders (ICDs) in people with Parkinson's disease (PD). These experts represented fields such as neurology, psychiatry, neurobiology, pharmacology, addiction, neurologic imaging, and epidemiology. Discussions centered on current knowledge of the actions of dopaminergic therapies at the molecular level, in animal models, in people with drug or behavioral addiction, and in PD patients. These discussions helped foster new collaborations and new study proposals that focused on clinical, preclinical, or translational approaches to continuing research in these disorders.

The proceedings of the conference will be published as a supplement or special issue in an appropriate journal. This meeting was built on the progress made since the initial conference in July 2007.

 

Organizing Committee

Mark Stacy, MD, Duke University Medical Center, USA
Anthony Lang, MD, University of Toronto, Canada
Michael Samuel, MD, King's College Hospital, London, UK
Antonio P. Strafella, MD, University of Toronto, Canada
Daniel Weintraub, MD, University of Pennsylvania, USA
Wendy Galpern, NIH, USA
David Shurtleff, NIH, USA

Agenda

DAY 1
1   Clinical overview of ICDs, DDS and related disorders
8:00-8:20 Global and individual impact and meeting rationale: (Mark Stacy)
8:20-8:40 Clinical perspective on unanswered questions: (Anthony Lang)
8:40-9:00 Assessment and Measurement of ICD: (Daniel Weintraub)
9:00-9:40 Discussion: David Shurtleff, Celeste Napier, TBA and Speakers
2   Understanding ICD mechanisms
10:20-10:40 Neurocircuitry and physiology  (Anthony Grace)
10:40-11:00 Electrophysiology in animal models (Jamie Roitman)
11:00-11:20 In vivo models of impulsivity (Catherine Winstanley)
11:20-11:40 In vivo models of addiction in Parkinson's Disease (Celeste Napier)
11:40-12:30 Discussion: David Shurtleff, Antonio Strafella and Speakers
3   What has imaging taught us about ICDs
1:30-1:50 Human imaging studies - dopaminergic system (Antonio Strafella)
1:50-2:10 Other imaging modalities (James Rowe)
2:10-2:40 Discussion: Anthony Grace, David Shurtleff, Valerie Voon and Speakers
4   Predispositions/correlates for the development of ICDs
3:00-3:20 Predispositions for ICDs in the general population (Jon Grant)
3:30-3:40 Psychiatric (Anthony David)
3:40-4:00 Cognitive (Valerie Voon)
4:00-4:20 Genetic Predisposition (Jean-Christophe Corvol)
4:20-5:00 Discussion: Daniel Weintraub, Catherine Winstanley, Richard Brown and Speakers
5:00  Poster Presentations

DAY 2

5   Therapeutic Approaches
A   Pharmacological
8:00-8:20 Why adjust the oral dopamine agonists in ICD? (Andrew Evans)
8:20-8:40 ICD/DDS and continuous apomorphine and rotigotine (K. Ray Chaudhuri)
8:40-9:00 Do levodopa, rasagiline and entacapone aggravate ICDs? (Michael Okun)
9:00-9.20 ICD/DDS and continuous levodopa infusion? (Angelo Antonini)
9:20-9:40 ICD/addiction and opioid and glutamatergic systems? (Daniel Weintraub)
9:40-10:00 Discussion: Jonathan Brotchie, Mike Samuel, Catherine Winstanley and Speakers
B   Non- Pharmacological
10:40-11:00 Clinical effects of DBS with respect to ICD and DDS (Michael Samuel)
11:00-11:20 STN recording in ICDs and dyskinesias? (Maria Rodriguez-Oroz)
11:20-11:40 Cognitive Behavior Therapy (Richard Brown)
11:40-12:30 Discussion: Anthony Lang, Jose Obeso, Jamie Roitman and Speakers
6   Potential Therapeutic Targets
1:30-1:50 Clinical Trials for ICD/DDS (Wendy Galpern)
1:50-2:10 Pharmacologic Targets (Jonathan Brotchie)
2:10-2:30 Physiologic Targets (Jose Obeso)
2:30-3:30 Discussion: Jean-Christophe Corvol, Celeste Napier, Daniel Weintraub and Speakers
7   Closing remarks
3:30-3:50 (Mark Stacy)

Sponsorship

Impulse Control Disorders in Parkinson's Disease was sponsored by the following: